257 related articles for article (PubMed ID: 24198302)
1. Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine.
Bergenstal RM; Rosenstock J; Bastyr EJ; Prince MJ; Qu Y; Jacober SJ
Diabetes Care; 2014; 37(3):659-65. PubMed ID: 24198302
[TBL] [Abstract][Full Text] [Related]
2. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.
Bergenstal RM; Rosenstock J; Arakaki RF; Prince MJ; Qu Y; Sinha VP; Howey DC; Jacober SJ
Diabetes Care; 2012 Nov; 35(11):2140-7. PubMed ID: 22787177
[TBL] [Abstract][Full Text] [Related]
3. A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin.
Manner DH; Luo J; Qu Y; Berry S; Gaydos BL; Jacober SJ
Diabetes Technol Ther; 2014 Aug; 16(8):499-505. PubMed ID: 24825416
[TBL] [Abstract][Full Text] [Related]
4. Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.
Jacober SJ; Rosenstock J; Bergenstal RM; Prince MJ; Qu Y; Beals JM
Diabetes Obes Metab; 2014 Apr; 16(4):351-6. PubMed ID: 24719911
[TBL] [Abstract][Full Text] [Related]
5. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.
Sinha VP; Howey DC; Choi SL; Mace KF; Heise T
Diabetes Obes Metab; 2014 Apr; 16(4):344-50. PubMed ID: 24118909
[TBL] [Abstract][Full Text] [Related]
6. Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8.
Harris C; Forst T; Heise T; Plum-Mörschel L; Watkins E; Zhang Q; Fan L; Garhyan P; Porksen N
Diabetes Technol Ther; 2017 Aug; 19(8):463-470. PubMed ID: 28817342
[TBL] [Abstract][Full Text] [Related]
7. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study.
Rosenstock J; Bergenstal RM; Blevins TC; Morrow LA; Prince MJ; Qu Y; Sinha VP; Howey DC; Jacober SJ
Diabetes Care; 2013 Mar; 36(3):522-8. PubMed ID: 23193209
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
[TBL] [Abstract][Full Text] [Related]
9. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.
Arakaki RF; Blevins TC; Wise JK; Liljenquist DR; Jiang HH; Jacobson JG; Martin SA; Jackson JA
Diabetes Obes Metab; 2014 Jun; 16(6):510-8. PubMed ID: 24298995
[TBL] [Abstract][Full Text] [Related]
10. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
Sinha VP; Choi SL; Soon DK; Mace KF; Yeo KP; Lim ST; Howey DC
J Clin Pharmacol; 2014 Jul; 54(7):792-9. PubMed ID: 24504686
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
[TBL] [Abstract][Full Text] [Related]
12. Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes.
Jovanovič L; Peters AL; Jiang HH; Hardin DS
Aging Clin Exp Res; 2014 Apr; 26(2):115-21. PubMed ID: 24092662
[TBL] [Abstract][Full Text] [Related]
13. Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial.
Morrow LA; Hompesch M; Jacober SJ; Leng Choi S; Qu Y; Sinha VP
Diabetes Obes Metab; 2016 Nov; 18(11):1065-1071. PubMed ID: 27169522
[TBL] [Abstract][Full Text] [Related]
14. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Yki-Järvinen H; Bergenstal R; Ziemen M; Wardecki M; Muehlen-Bartmer I; Boelle E; Riddle MC;
Diabetes Care; 2014 Dec; 37(12):3235-43. PubMed ID: 25193531
[TBL] [Abstract][Full Text] [Related]
15. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.
Tinahones FJ; Gross JL; Onaca A; Cleall S; Rodríguez A
Diabetes Obes Metab; 2014 Oct; 16(10):963-70. PubMed ID: 24725616
[TBL] [Abstract][Full Text] [Related]
16. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z
Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266
[TBL] [Abstract][Full Text] [Related]
17. Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D.
Blevins T; Zhang Q; Frias JP; Jinnouchi H; Chang AM;
Diabetes Care; 2020 Dec; 43(12):2991-2998. PubMed ID: 32616612
[TBL] [Abstract][Full Text] [Related]
18. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P
JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317
[TBL] [Abstract][Full Text] [Related]
19. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
Riddle MC; Bolli GB; Ziemen M; Muehlen-Bartmer I; Bizet F; Home PD;
Diabetes Care; 2014 Oct; 37(10):2755-62. PubMed ID: 25078900
[TBL] [Abstract][Full Text] [Related]
20. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes.
Buse JB; Wolffenbuttel BH; Herman WH; Shemonsky NK; Jiang HH; Fahrbach JL; Scism-Bacon JL; Martin SA
Diabetes Care; 2009 Jun; 32(6):1007-13. PubMed ID: 19336625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
